company background image
MXC logo

MGC Pharmaceuticals ASX:MXC Stock Report

Last Price

AU$0.41

Market Cap

AU$18.4m

7D

-5.7%

1Y

-95.9%

Updated

28 Mar, 2024

Data

Company Financials

MGC Pharmaceuticals Limited

ASX:MXC Stock Report

Market Cap: AU$18.4m

MGC Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MGC Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.41
52 Week HighAU$11.00
52 Week LowAU$0.30
Beta1.03
1 Month Change9.33%
3 Month Change-13.68%
1 Year Change-95.90%
3 Year Change-99.32%
5 Year Change-98.83%
Change since IPO-99.72%

Recent News & Updates

Recent updates

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Jun 23
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Mar 09
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

Oct 08
Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21
If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Dec 30
What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Shareholder Returns

MXCAU PharmaceuticalsAU Market
7D-5.7%1.1%1.5%
1Y-95.9%44.7%11.6%

Return vs Industry: MXC underperformed the Australian Pharmaceuticals industry which returned 44.7% over the past year.

Return vs Market: MXC underperformed the Australian Market which returned 11.6% over the past year.

Price Volatility

Is MXC's price volatile compared to industry and market?
MXC volatility
MXC Average Weekly Movement14.6%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement8.7%
10% most volatile stocks in AU Market17.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: MXC's share price has been volatile over the past 3 months.

Volatility Over Time: MXC's weekly volatility has decreased from 39% to 15% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2014n/aRoby Zomerhttps://mgcpharma.com.au

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.

MGC Pharmaceuticals Limited Fundamentals Summary

How do MGC Pharmaceuticals's earnings and revenue compare to its market cap?
MXC fundamental statistics
Market capAU$18.42m
Earnings (TTM)-AU$17.02m
Revenue (TTM)AU$1.32m

13.6x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MXC income statement (TTM)
RevenueAU$1.32m
Cost of RevenueAU$1.20m
Gross ProfitAU$125.39k
Other ExpensesAU$17.14m
Earnings-AU$17.02m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.39
Gross Margin9.47%
Net Profit Margin-1,284.89%
Debt/Equity Ratio1,366.5%

How did MXC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.